Acacia Pharma Group plc Stock

ACPH

GB00BYWF9Y76

OTC Markets Traded

Latest news : Acacia Pharma Group plc

07-16	Acacia Pharma Group plc Announces the Termination of Debra Marie Hussain as Director, Effective July 13, 2026	CI
25-02-03	Acacia Pharma Group plc Auditor Raises 'Going Concern' Doubt	CI
25-02-03	Acacia Pharma Group plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-07-21	Acacia Pharma Limited Appoints Debra Marie Hussain as Director	CI
22-06-09	Eagle Pharmaceuticals Completes Acacia Pharma Acquisition	MT
22-06-09	Acacia Pharma's Acquisition by Eagle Pharmaceuticals Closes; Shares Delist	MT
22-06-08	Acacia Pharma Group plc(ENXTBR:ACPH) dropped from Next Biotech Index	CI
22-06-07	Acacia Pharma's Acquisition by Eagle Pharmaceuticals Nears Completion	MT
22-06-05	Eagle Pharmaceuticals, Inc. completed the acquisition of Acacia Pharma Group plc from a group of shareholders.	CI
22-04-28	Acacia Pharma Group plc Auditor Raises 'Going Concern' Doubt	CI
22-04-28	Acacia Pharma Group plc Reports Earnings Results for the Full Year Ended December 31, 2021	CI
22-03-28	Health Care Up on Revival of Demand for Growth Sectors -- Health Care Roundup	DJ
22-03-28	FTSE 100 Closes Lower Despite Earlier Hopes on Russia, Ukraine Talks	DJ

More news

Analysts' recommendations: Acacia Pharma Group plc

21-10-01

Analyst recommendations: Acceleron Pharma, General Mills, Southwest Airlines, Home Depot, Wizz Air...

More recommendations

Press Releases: Acacia Pharma Group plc

22-06-09	Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint	AQ
22-06-09	Scheme of arrangement becoming effective	GL
22-06-09	Scheme of arrangement becoming effective	AQ
22-06-07	Court Sanction of the Scheme of Arrangement	GL
22-06-07	Court Sanction of the Scheme of Arrangement	AQ

More press releases

News in other languages: Acacia Pharma Group plc

22-06-07	Bel20 beperkt zijn verliezen bij het slot
22-06-07	Brussel in het rood
22-06-07	Overname Acacia afgerond
22-05-20	Bel20 sluit week hoger af
22-05-20	Brussel omhoog

More news

Managers and Directors: Acacia Pharma Group plc

Manager	Title	Age	Since
Gabriel Fox CTO	Chief Tech/Sci/R&D Officer	-	2007-12-31
Debra M. Hussain PRN	Corporate Officer/Principal	-	2021-05-18
Anne-Marie Elsley SEC	Corporate Secretary	-	2020-02-28

Director	Title	Age	Since
Scott A. Byrd CHM	Chairman	56	2020-03-01
John Brown BRD	Director/Board Member	71	2018-02-28
Ed Borkowski BRD	Director/Board Member	66	2018-02-28

More insiders

Acacia Pharma Group plc specializes in the research and development of supportive care medicines. The products are intended to support the side effects of anti-cancer treatments (including nausea and vomiting drugs). At the end of 2021, the group had a portfolio of 3 products, including 1 in phase II of clinical development (APD403; treatment of chemically induced nausea and vomiting) and 2 in pre-launch phase: BARHEMSYS (treatment of nausea and postoperative vomiting) and BYFAVO (benzodiazepine sedative for use in invasive medical procedures in adults, such as colonoscopy and bronchoscopy).

Employees

Sector

More about the company

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/23/22	Michael Bolinder	Fiscal year	Chief Executive Officer	63,710	0.0632%
1/8/22	John Brown	Buy	Director	5,001	0.0050%
1/8/22	Scott A. Byrd	Buy	Chairman	5,062	0.0050%